What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Visual acuity
- Surgery
Her main research concerns Ophthalmology, Visual acuity, Surgery, Macular degeneration and Eye disease.
While the research belongs to areas of Ophthalmology, she spends her time largely on the problem of Retina, intersecting her research to questions surrounding Nerve fiber.
Her biological study spans a wide range of topics, including Clinical trial, Optic neuritis, Audiology and Contrast.
Her Randomized controlled trial study in the realm of Surgery connects with subjects such as Pseudotumor cerebri.
Her study in Macular degeneration is interdisciplinary in nature, drawing from both Prospective cohort study and Ranibizumab.
Her Ranibizumab research incorporates themes from Lower risk and Confidence interval.
Her most cited work include:
- Ranibizumab and bevacizumab for neovascular age-related macular degeneration. (1886 citations)
- Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis (1728 citations)
- Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. (1180 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Ophthalmology, Macular degeneration, Visual acuity, Surgery and Internal medicine.
As a member of one scientific family, Maureen G. Maguire mostly works in the field of Ophthalmology, focusing on Randomized controlled trial and, on occasion, Placebo.
The study incorporates disciplines such as Pro re nata, Prospective cohort study, Incidence and Age related in addition to Macular degeneration.
Her research integrates issues of Diabetic retinopathy, Clinical trial, Optometry, Aflibercept and Ranibizumab in her study of Visual acuity.
Her Surgery study combines topics in areas such as Diabetes mellitus, Relative risk and Cohort study.
Her Internal medicine study incorporates themes from Gastroenterology and Cardiology.
She most often published in these fields:
- Ophthalmology (48.12%)
- Macular degeneration (30.99%)
- Visual acuity (27.93%)
What were the highlights of her more recent work (between 2017-2021)?
- Ophthalmology (48.12%)
- Macular degeneration (30.99%)
- Internal medicine (16.90%)
In recent papers she was focusing on the following fields of study:
Her primary areas of investigation include Ophthalmology, Macular degeneration, Internal medicine, Visual acuity and Randomized controlled trial.
The various areas that Maureen G. Maguire examines in her Ophthalmology study include Retinopathy of prematurity and Intraclass correlation.
Her research in Macular degeneration is mostly focused on Choroidal neovascularization.
Her work in the fields of Internal medicine, such as Odds ratio, Disease and Cohort, intersects with other areas such as Ocular Surface Disease Index.
Maureen G. Maguire has researched Visual acuity in several fields, including Diabetic retinopathy, Diabetic macular edema, Ranibizumab and Post-hoc analysis.
Her Randomized controlled trial research is multidisciplinary, incorporating elements of Interquartile range, Cohort study, Confidence interval, Placebo and Aflibercept.
Between 2017 and 2021, her most popular works were:
- n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. (81 citations)
- Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. (46 citations)
- Early Response to Anti–Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T (35 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Visual acuity
- Ophthalmology
Ophthalmology, Visual acuity, Randomized controlled trial, Ranibizumab and Internal medicine are her primary areas of study.
Her work on Meibomian gland as part of general Ophthalmology research is frequently linked to Linear mixed effect model, bridging the gap between disciplines.
In her research, Atrophy is intimately related to Macular degeneration, which falls under the overarching field of Visual acuity.
Her studies deal with areas such as Placebo, Interquartile range, Aflibercept and Confidence interval as well as Randomized controlled trial.
Her Ranibizumab research integrates issues from Clinical trial and Diabetic macular edema.
Her Cohort study research is multidisciplinary, incorporating perspectives in Diabetes mellitus, Relative risk and Surgery.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
